Home > Documents in Process > Serum level changes of the synaptic marker beta-synuclein in Alzheimer's disease continuum and other dementias. > print

001     282296
005     20251117094801.0
024 7 _ |a 10.1136/jnnp-2025-336189
|2 doi
024 7 _ |a pmid:40571405
|2 pmid
024 7 _ |a 0022-3050
|2 ISSN
024 7 _ |a 0266-8637
|2 ISSN
024 7 _ |a 0368-329X
|2 ISSN
024 7 _ |a 1468-330X
|2 ISSN
024 7 _ |a 2753-0477
|2 ISSN
024 7 _ |a 2753-0485
|2 ISSN
037 _ _ |a DZNE-2025-01266
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Barba, Lorenzo
|0 0000-0003-1328-3620
|b 0
245 _ _ |a Serum level changes of the synaptic marker beta-synuclein in Alzheimer's disease continuum and other dementias.
260 _ _ |a London
|c 2025
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763369178_17168
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Beta-synuclein is an emerging blood biomarker for detecting synaptic damage in Alzheimer's disease (AD) but its role in early AD as well as in other dementias is unclear.We measured with immunoprecipitation mass-spectrometry serum beta-synuclein levels in an exploratory cohort of 80 patients recruited at the University of Perugia (Perugia, Italy) (n=56 AD; n=24 controls) and in a validation cohort of 269 patients recruited at the University of Barcelona (Barcelona, Spain) (n=108 AD; n=53 frontotemporal lobar degeneration (FTLD); n=73 dementia with Lewy bodies and mild cognitive impairment (MCI) with Lewy bodies, together Lewy body disease (LBD); n=27 controls). We tested associations with diagnostic groups, cognitive decline and other cerebrospinal fluid (CSF) and blood markers (phosphorylated tau protein in position 181 (pTau181), neurofilament light chain protein (NfL), glial fibrillar acidic protein (GFAP)).Serum beta-synuclein level was progressively increased in the AD continuum across the preclinical, MCI and dementia stages compared with controls and was correlated with serum pTau181 (r=0.710), NfL (r=0.494) and GFAP concentrations (r=0.621, p<0.001 for all). The biomarker showed high accuracy for the discrimination of AD vs controls (area under the curve (AUC): 0.87) and AD-MCI vs non-AD MCI (AUC: 0.96). High serum beta-synuclein level was correlated with lower Mini-Mental State Examination (MMSE) points at baseline (r=-0.461, p<0.001) and associated with MMSE change at follow-up after accounting for age, sex and the time from baseline to last follow-up visit (p=0.006). Serum beta-synuclein level was similar between FTLD and controls, whereas, in LBD, it was higher with AD copathology as evidenced by CSF analysis (p<0.001).High serum beta-synuclein level is a promising biomarker for AD-related synaptic damage.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ALZHEIMER'S DISEASE
|2 Other
650 _ 7 |a FRONTOTEMPORAL DEMENTIA
|2 Other
650 _ 7 |a LEWY BODY DEMENTIA
|2 Other
650 _ 7 |a NEUROCHEMISTRY
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a beta-Synuclein
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Alzheimer Disease: blood
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Lewy Body Disease: blood
|2 MeSH
650 _ 2 |a Lewy Body Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: blood
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: blood
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a beta-Synuclein: blood
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: blood
|2 MeSH
650 _ 2 |a Frontotemporal Lobar Degeneration: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: blood
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Dementia: blood
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
700 1 _ |a Bellomo, Giovanni
|b 1
700 1 _ |a Alcolea, Daniel
|0 0000-0002-3819-3245
|b 2
700 1 _ |a Wojdala, Anna L
|b 3
700 1 _ |a Gaetani, Lorenzo
|b 4
700 1 _ |a Fortea, Juan
|0 0000-0002-1340-638X
|b 5
700 1 _ |a Abu-Rumeileh, Samir
|0 0000-0003-0631-8506
|b 6
700 1 _ |a Lleó, Alberto
|0 0000-0002-2568-5478
|b 7
700 1 _ |a Parnetti, Lucilla
|0 0000-0001-5722-3967
|b 8
700 1 _ |a Belbin, Olivia
|b 9
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 10
700 1 _ |a Oeckl, Patrick
|0 P:(DE-2719)9001560
|b 11
|e Last author
773 _ _ |a 10.1136/jnnp-2025-336189
|g Vol. 96, no. 12, p. jnnp-2025-336189 -
|0 PERI:(DE-600)1480429-3
|n 12
|p 1144 - 1153
|t Journal of neurology, neurosurgery, and psychiatry
|v 96
|y 2025
|x 0022-3050
856 4 _ |u https://pub.dzne.de/record/282296/files/DZNE-2025-01266_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/282296/files/DZNE-2025-01266_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9001560
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL NEUROSUR PS : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-28
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J NEUROL NEUROSUR PS : 2022
|d 2024-12-28
920 1 _ |0 I:(DE-2719)5000073
|k AG Öckl
|l Translational Mass Spectrometry and Biomarker Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000073
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21